激素抵抗型肾病综合征的基因检测:何时与如何进行?
激素抵抗型肾病综合征(SRNS)是30岁前慢性肾脏病的第二大常见病因,组织学表现为局灶节段性肾小球硬化(FSGS),肾移植后复发风险为33%。在25岁前发病的SRNS个体中,约30%可检出约30个SRNS致病基因之一的致病突变,因此建议所有25岁前发病的SRNS个体接受突变分析。
要点
- SRNS是30岁前慢性肾脏病的第二大常见病因,肾移植后复发风险为33%。
- 25岁前发病的SRNS个体中约30%可检出约30个致病基因之一的致病突变。
- 建议所有25岁前发病的SRNS个体接受突变分析,以获取病因诊断并指导精准治疗。
核心结论
- SRNS和FSGS并非单一疾病实体,而是具有可识别遗传病因的多种不同疾病谱的一部分。
- 建议所有25岁前发病的SRNS个体接受突变分析,理由包括提供明确的病因诊断、可能发现可治疗的类型(如辅酶Q10)、可能避免肾活检、进一步揭示致病通路以及实现基于遗传病因的精准医学个体化治疗。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- SRNS是30岁前慢性肾脏病的第二大常见病因,组织学表现为FSGS,肾移植后复发风险为33%。
- 已发现超过30个隐性或显性基因的突变可导致单基因型SRNS,所编码蛋白对肾小球功能至关重要。
- 在25岁前发病的SRNS个体中,约30%可检出约30个SRNS致病基因之一的致病突变。
关键数值与推荐
- 约30%的25岁前发病SRNS个体可检出约30个SRNS致病基因之一的致病突变。
- 肾移植后SRNS复发风险为33%。
临床怎么用
- 建议所有25岁前发病的SRNS个体接受突变分析,以提供病因诊断、发现可治疗类型、避免肾活检、揭示致病通路并实现精准医学个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-resistant nephrotic syndrome (SRNS) represents the second most frequent cause of chronic kidney disease in the first three decades of life. It manifests histologically as focal segmental glomerulosclerosis (FSGS) and carries a 33% risk of relapse in a renal transplant. No efficient treatment exists. Identification of single-gene (monogenic) causes of SRNS has moved the glomerular epithelial cell (podocyte) to the center of its pathogenesis. Recently, mutations in >30 recessive or dominant genes were identified as causing monogenic forms of SRNS, thereby revealing the encoded proteins as essential for glomerular function. These findings helped define protein interaction complexes and functional pathways that could be targeted for treatment of SRNS. Very recently, it was discovered that in the surprisingly high fraction of ∼30% of all individuals who manifest with SRNS before 25 years of age, a causative mutation can be detected in one of the ∼30 different SRNS-causing genes. These findings revealed that SRNS and FSGS are not single disease entities but rather are part of a spectrum of distinct diseases with an identifiable genetic etiology. Mutation analysis should be offered to all individuals who manifest with SRNS before the age of 25 years, because (i) it will provide the patient and families with an unequivocal cause-based diagnosis, (ii) it may uncover a form of SRNS that is amenable to treatment (e.g. coenzyme Q10), (iii) it may allow avoidance of a renal biopsy procedure, (iv) it will further unravel the puzzle of pathogenic pathways of SRNS and (v) it will permit personalized treatment options for SRNS, based on genetic causation in way of 'precision medicine'.
引用
- Lovric S, Ashraf S, Tan W, et al. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant. 2015. PMID: 26507970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。